Stephen C. Glover, co-founder, chairman, CEO and president of ZyVersa Therapeutics Inc. ZVSA, was recently a panelist at Benzinga's Virtual HealthCare Summit 2024.
ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop transformative drugs for underserved patients with renal and inflammatory diseases. The company is advancing a therapeutic pipeline with multiple programs built around its proprietary technologies – VAR 200 and IC 100.
The innovative focus on inflammation shows promising results in diseases from Parkinson’s to Sclerosis.
Learn more here:
Featured photo by Louis Reed on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
